Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.33 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31299701 | 0.98 | TSHR (0.42) | TSHRMAPTABCC4ALDH1A1LMNA | |
| SCHEMBL1273701 | 0.92 | — | — | |
| SCHEMBL27913147 | 0.83 | LPAR2 (0.33) | TSHRMAPTABCC4LPAR2LPAR3 | |
| SCHEMBL1167256 | 0.81 | — | — | |
| SCHEMBL11323118 | 0.79 | TSHR (0.42) | TSHRMAPTABCC4ALDH1A1LMNA | |
| SCHEMBL22808130 | 0.79 | TSHR (0.42) | TSHRMAPTABCC4ALDH1A1LMNA | |
| SCHEMBL2263006 | 0.78 | APLNR (0.32) | FAAH | |
| SCHEMBL19644547 | 0.77 | TSHR (0.46) | TSHRMAPTABCC4ALDH1A1LMNA | |
| SCHEMBL20972793 | 0.77 | TSHR (0.46) | TSHRMAPTABCC4ALDH1A1LMNA | |
| SCHEMBL8243462 | 0.75 | CA2 (0.43) | TSHRMAPTABCC4ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11976083-B2 | Inhibitors of peptidylarginine deiminases | GILEAD SCIENCES, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| CN-115551862-B | Macrocyclic inhibitors of peptidyl arginine deiminase | 吉利德科学公司 | 2024-04-12 | — | — | CN | disclosed |
| EP-4143189-A1 | MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20230002412-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. | 2023-01-05 | — | — | US | disclosed |
| CN-115551862-A | Macrocyclic inhibitors of peptidyl arginine deiminase | 吉利德科学公司 | 2022-12-30 | — | — | CN | disclosed |
| WO-2021222353-A1 | MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| EP-2834288-B1 | COLORED CHARGED SILSESQUIOXANES | BASF SE (DE) | 2017-04-26 | — | — | EP | disclosed |
| US-9228063-B2 | Colored charged silsesquioxanes | BASF SE (DE) | 2016-01-05 | — | — | US | disclosed |
| US-9228063-B2 | Colored charged silsesquioxanes | BASF SE (DE) | 2016-01-05 | — | — | US | disclosed |
| EP-1879607-B1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2014-11-12 | — | — | EP | disclosed |
| WO-2013150444-A1 | COLORED CHARGED SILSESQUIOXANES | BASF SE (DE) | 2013-10-10 | — | — | WO | disclosed |
| WO-2013013240-A2 | MACROCYCLIC COMPOUNDS AND RELATED COMPOSITONS AND METHODS OF USE | THERACRINE, INC. (US) | 2013-01-24 | — | — | WO | disclosed |
| WO-2013013240-A2 | MACROCYCLIC COMPOUNDS AND RELATED COMPOSITONS AND METHODS OF USE | THERACRINE, INC. (US) | 2013-01-24 | — | — | WO | disclosed |
| US-20120094897-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094897-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| WO-2012037259-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| US-7879797-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20090075869-A1 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME LLC | 2009-03-19 | — | — | US | disclosed |
| EP-1879607-A2 | HCV NS3 PROTEASE INHIBITORS | Merck & Co., Inc. (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006119061-A2 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094897-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HDGF | TSHR 4726/4885MAPT 4380/4885ABCC4 4218/4885 |
| US-20090075869-A1 | HCV NS3 protease inhibitors | HAVCR2, GTF3C3, CTSC | TSHR 4610/4885MAPT 4330/4885ABCC4 900/4885 |
| US-11976083-B2 | Inhibitors of peptidylarginine deiminases | PADI4, PADI2, PADI1 | TSHR 1815/4885MAPT 3578/4885ABCC4 2818/4885 |
| US-20230002412-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | PADI4, PADI2, PADI1 | TSHR 1815/4885MAPT 3578/4885ABCC4 2818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.